Mechanism of indinavir-induced hyperbilirubinemia
Indinavir is a viral protease inhibitor used for the treatment of HIV infection. Unconjugated hyperbilirubinemia develops in up to 25% of patients receiving indinavir, prompting drug discontinuation and further clinical evaluation in some instances. We postulated that this side-effect is due to indi...
Guardat en:
| Publicat a: | Proc Natl Acad Sci U S A |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
National Academy of Sciences
2001
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC60112/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11606755/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.231140698 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|